Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss

Bipolar androgen therapy (BAT) relies on oscillating levels of serum testosterone as a way to treat patients with metastatic castration-resistant prostate cancer (mCRPC). Aggressive-variant prostate cancers typically require combination chemotherapy and are frequently associated with loss-of-functio...

Descripción completa

Detalles Bibliográficos
Autores principales: Markowski, Mark C., Wang, Hao, De Marzo, Angelo M., Schweizer, Michael T., Antonarakis, Emmanuel S., Denmeade, Samuel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168525/
https://www.ncbi.nlm.nih.gov/pubmed/35677016
http://dx.doi.org/10.1016/j.euros.2022.05.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168525/
https://www.ncbi.nlm.nih.gov/pubmed/35677016
http://dx.doi.org/10.1016/j.euros.2022.05.006

Ejemplares similares